Pur­due's mul­ti-bil­lion dol­lar set­tle­ment in jeop­ardy af­ter fed­er­al judge toss­es deal; Bio­Marin an­nounces glob­al gene ther­a­py col­lab­o­ra­tion

Well, Pur­due Phar­ma’s mul­ti-bil­lion dol­lar opi­oid set­tle­ment is now in jeop­ardy — a fed­er­al judge just said no.

Colleen McMa­hon, a judge on the US Dis­trict Court for the South­ern Dis­trict of New York, said that the set­tle­ment, which would dis­solve Pur­due Phar­ma and was ap­proved in Sep­tem­ber by a bank­rupt­cy judge, should not go for­ward be­cause it re­leas­es the com­pa­ny’s own­ers, mem­bers of the bil­lion­aire Sack­ler fam­i­ly, from li­a­bil­i­ty in civ­il opi­oid-re­lat­ed cas­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.